BioTroy

About BioTroy

BioTroy is a clinical-stage biopharmaceutical company developing therapies for cancer and immunological disorders. Founded in 2019 by Dr. Jie Xu, a senior researcher in translational oncology and oncoimmunotherapy, the company is headquartered in Shanghai, China. Dr. Xu's research into cancer immune evasion and immune checkpoint pathways forms the scientific foundation of the company.

The company's business model centers on the discovery and development of 'first-in-class' drugs, focusing on original tumor immunotherapy targets. It utilizes its proprietary 'BioTroy Engine' platform, which integrates multi-omics analysis, functional biology, and antibody engineering to identify and validate novel therapeutic targets. This platform has produced several discoveries, including the company's leading assets, BT01 and BT02. BT02, a monoclonal antibody, has received Investigational New Drug (IND) clearance from both the U.S. FDA and China's NMPA and is advancing into clinical trials for solid tumors.

BioTroy serves patients with cancer, particularly those with tumors unresponsive to existing PD-1/PD-L1 inhibitors. The company operates in the competitive biotechnology and cancer immunotherapy market. It generates value through the development and potential commercialization of its drug pipeline, backed by a global intellectual property portfolio covering its discoveries. BioTroy has secured significant funding, raising over RMB 150 million (~$21 million USD) from investors including Shanghai Healthcare Capital, Lapam Capital, and Pudong Capital to support its research and development activities.